Outcome of use of regorafenib in metastatic colorectal cancer in routine clinic practice in Saudi Arabia.

e15021Background: Regorafenib is a multi-kinase inhibitor that was FDA approved for the treatment of refractory advanced colorectal cancer. It has been found in the clinical trials to have modest b...